Physician profile
David Provaznik
NPI 1245267624
$7,923.75
in general payments reported to CMS, 2019-2025
48 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $1,098 · 2021: $1,108 · 2022: $979 · 2023: $1,231 · 2024: $1,106 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,450 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.79 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,804.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $719.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $642.23 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.06 | 2019-2025 | Jardiance |
| Amgen INC. | $331.78 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $274.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $250.64 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $250.40 | 2020-2023 | Livalo, Seglentis |
| Abbvie INC. | $248.73 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $235.12 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $218.91 | 2020-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $194.16 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $179.27 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.44 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $163.47 | 2020-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Provaznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.